Since TNBC is highly immunogenic with higher PD-L1 expression and immune-infiltration compared with luminal and HER2-enriched breast cancers, immunotherapy has been represented as a promising treatment strategy for TNBC [35,36]. This evidence concerns the gene ERBB2 and breast carcinoma.